BrainsWay Ltd. (BWAY)
- Previous Close
8.71 - Open
8.88 - Bid --
- Ask --
- Day's Range
8.70 - 9.09 - 52 Week Range
5.13 - 11.79 - Volume
28,086 - Avg. Volume
54,472 - Market Cap (intraday)
167.395M - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
49.28 - EPS (TTM)
0.18 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.55
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
www.brainsway.comRecent News: BWAY
View MorePerformance Overview: BWAY
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BWAY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BWAY
View MoreValuation Measures
Market Cap
165.73M
Enterprise Value
102.00M
Trailing P/E
49.28
Forward P/E
38.61
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
2.69
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
19.04
Financial Highlights
Profitability and Income Statement
Profit Margin
7.12%
Return on Assets (ttm)
1.10%
Return on Equity (ttm)
5.62%
Revenue (ttm)
41.02M
Net Income Avi to Common (ttm)
2.92M
Diluted EPS (ttm)
0.18
Balance Sheet and Cash Flow
Total Cash (mrq)
69.34M
Total Debt/Equity (mrq)
9.02%
Levered Free Cash Flow (ttm)
3.66M